Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment
3.2. Snippet by Disease Stage
3.3. Snippet by Patient Age
3.4. Snippet by End-User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of primary sclerosing cholangitis
4.1.2. Restraints
4.1.2.1. Side effects associated with primary sclerosing cholangitis
4.1.3. Opportunity
4.1.3.1. Technological advancements
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Russia-Ukraine Analysis
5.8. Artificial Intelligence Impact
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Medication-based Therapies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Bile acid sequestrants
7.2.4. Antibiotics
7.2.5. Antihistamines
7.2.6. Opioid antagonists
7.2.7. Ursodeoxycholic acid (UDCA)
7.3. Bile Duct Blockages
7.3.1. Balloon dilation
7.3.2. Stent placement
7.4. Liver Transplantation
8. By Disease Stage
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
8.1.2. Market Attractiveness Index, By Disease Stage
8.2. Early-stage*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Moderate-stage
8.4. Advanced-stage
9. By Patient Age
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
9.1.2. Market Attractiveness Index, By Patient Age
9.2. Child*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Adult
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Stage
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Age
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies
13. Company Profiles
13.1. Intercept Pharmaceuticals*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Gilead Sciences
13.3. Bristol Myers Squibb
13.4. Takeda Pharmaceutical Company Limited
13.5. Johnson & Johnson
13.6. Allergan
13.7. Genfit
13.8. Pliant Therapeutics
13.9. ChemomAb Therapeutics Ltd.
13.10. Dr. Falk Pharma
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us